Literature DB >> 31152668

Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.

Emil Lou1, Rachel I Vogel2, Spencer Hoostal3, Molly Klein4, Michael A Linden4, Deanna Teoh2, Melissa A Geller2.   

Abstract

Entities:  

Year:  2019        PMID： 31152668      PMCID： PMC6547254          DOI： 10.1001/jamaoncol.2019.1943

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  6 in total

1.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

Review 2.  "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?

Authors:  Alison Davis; Anna V Tinker; Michael Friedlander
Journal:  Gynecol Oncol       Date:  2014-03-04       Impact factor: 5.482

3.  High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer

Authors:  Josipa Flam; Damir Gugić; Mirta Benšić; Snježana Tomić; Jasmina Rajc
Journal:  Acta Clin Croat       Date:  2017-03       Impact factor: 0.780

4.  Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.

Authors:  Paulette Mhawech-Fauceglia; Li Yan; Maryam Sharifian; Xing Ren; Song Liu; Grace Kim; Simon A Gayther; Tanja Pejovic; Kate Lawrenson
Journal:  Cancer Microenviron       Date:  2014-10-21

5.  Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer.

Authors:  Ying Chen; Lei Zhang; Wenxin Liu; Xiangyu Liu
Journal:  Biomed Res Int       Date:  2015-11-01       Impact factor: 3.411

6.  The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer.

Authors:  F J A Gujam; J Edwards; Z M A Mohammed; J J Going; D C McMillan
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640
  6 in total
  5 in total

1.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 2.  A Ticket to Ride: The Implications of Direct Intercellular Communication via Tunneling Nanotubes in Peritoneal and Other Invasive Malignancies.

Authors:  Emil Lou
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

3.  Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.

Authors:  Kaiyang Zhang; Erdogan Pekcan Erkan; Sanaz Jamalzadeh; Jun Dai; Noora Andersson; Katja Kaipio; Tarja Lamminen; Naziha Mansuri; Kaisa Huhtinen; Olli Carpén; Sakari Hietanen; Jaana Oikkonen; Johanna Hynninen; Anni Virtanen; Antti Häkkinen; Sampsa Hautaniemi; Anna Vähärautio
Journal:  Sci Adv       Date:  2022-02-23       Impact factor: 14.136

4.  The PDGF Family Is Associated with Activated Tumor Stroma and Poor Prognosis in Ovarian Cancer.

Authors:  Jiajia Li; Xiuling Zhi; Yating Sun; Mo Chen; Liangqing Yao
Journal:  Dis Markers       Date:  2022-09-26       Impact factor: 3.464

5.  Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio.

Authors:  Yiyu Hong; You Jeong Heo; Binnari Kim; Donghwan Lee; Soomin Ahn; Sang Yun Ha; Insuk Sohn; Kyoung-Mee Kim
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.